Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness

HealthHORIZON-RIAID: 101057454
EC Contribution
โ‚ฌ102,764
Consortium Size
31 orgs
Start Year
2022
โ–ถSummary

A key problem in Mental Health is that up to one third of patients suffering from major mental disorders develop resistance against drug therapy. However, patients showing early signs of treatment resistance (TR) do not receive adequate early intensive pharmacological treatment but instead they undergo a stepwise trial-and-error treatment approach. This situation originates from three major knowledge and translation gaps: i.) we lack effective methods to identify individuals at risk for TR early in the disease process, ii.) we lack effective, personalized treatment strategies grounded in insights into the biological basis of TR, and iii.) we lack efficient processes to translate scientific insights about TR into clinical practice, primary care and treatment guidelines. It is the central goal of PSYCH-STRATA to bridge these gaps and pave the way for a shift towards a treatment decision-making process tailored for the individual at risk for TR. To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for TR across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. PSYCH-STRATA will i.) dissect the biological basis of TR and establish criteria to enable early detection of individuals at risk for TR based on the integrated analysis of an unprecedented collection of genetic, biological, digital mental health, and clinical data. ii.) Moreover, we will determine effective treatment strategies of individuals at risk for TR early in the treatment process, based on pan-European clinical trials in SCZ, BD and MDD. These efforts will enable the establishment of novel multimodal machine learning models to predict TR risk and treatment response. Lastly, iii.) we will enable the translation of these findings into clinical practice by prototyping the integration of personalized treatment decision support and patient-oriented decision-making mental health boards.

Consortium (31)

๐Ÿ‡ฉ๐Ÿ‡ช UNIVERSITAET MUENSTERDE
coordinator
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
partner
๐Ÿ‡ฎ๐Ÿ‡น Associazione Oasi Maria SS. OnlusIT
partner
๐Ÿ‡ฌ๐Ÿ‡ง CARDIFF UNIVERSITYGB
partner
๐Ÿ‡ฉ๐Ÿ‡ช CHARITE - UNIVERSITAETSMEDIZIN BERLINDE
partner
๐Ÿ‡ฉ๐Ÿ‡ช EUROPEAN RESEARCH SERVICES GMBHDE
partner
๐Ÿ‡ฉ๐Ÿ‡ช FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EVDE
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO CENTRE DE REGULACIO GENOMICAES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYERES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANONES
partner
๐Ÿ‡ง๐Ÿ‡ช GLOBAL ALLIANCE OF MENTAL ILLNESS ADVOCACY NETWORKS EUROPE AISBLBE
partner
๐Ÿ‡ธ๐Ÿ‡ช GOETEBORGS UNIVERSITETSE
partner
๐Ÿ‡ช๐Ÿ‡ธ HOSPITAL CLINIC DE BARCELONAES
partner
๐Ÿ‡ซ๐Ÿ‡ท INSTITUT DU CERVEAU ET DE LA MOELLE EPINIEREFR
partner
๐Ÿ‡ฉ๐Ÿ‡ช KAIROS GMBHDE
partner
๐Ÿ‡ฉ๐Ÿ‡ช KARLSRUHER INSTITUT FUER TECHNOLOGIEDE
partner
๐Ÿ‡ง๐Ÿ‡ช KATHOLIEKE UNIVERSITEIT LEUVENBE
partner
๐Ÿ‡ฌ๐Ÿ‡ง KING'S COLLEGE LONDONGB
partner
๐Ÿ‡ฉ๐Ÿ‡ช KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHENDE
partner
๐Ÿ‡ฉ๐Ÿ‡ช LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHENDE
partner
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
partner
๐Ÿ‡จ๐Ÿ‡พ NOVAMECHANICS LIMITEDCY
partner
๐Ÿ‡ฌ๐Ÿ‡ท NOVAMECHANICS MONOPROSOPI IKEGR
partner
๐Ÿ‡ณ๐Ÿ‡ด OSLO UNIVERSITETSSYKEHUS HFNO
partner
๐Ÿ‡ฉ๐Ÿ‡ฐ REGION HOVEDSTADENDK
partner
๐Ÿ‡ฆ๐Ÿ‡บ THE UNIVERSITY OF ADELAIDEAU
partner
๐Ÿ‡ฎ๐Ÿ‡น UNIVERSITA DEGLI STUDI DI BRESCIAIT
partner
๐Ÿ‡ฎ๐Ÿ‡น UNIVERSITA DEGLI STUDI DI CAGLIARIIT
partner
๐Ÿ‡ณ๐Ÿ‡ฑ UNIVERSITAIR MEDISCH CENTRUM UTRECHTNL
partner
๐Ÿ‡ณ๐Ÿ‡ด UNIVERSITETET I OSLONO
partner
๐Ÿ‡จ๐Ÿ‡ญ WORLD PSYCHIATRIC ASSOCIATIONCH
partner